证券代码：600420 证券简称：国药现代 公告编号：2023-084 上海现代制药股份有限公司 第八届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海现代制药股份有限公司（以下简称公司）第八届监事会第五次会议，于 2023 年 8 月 28 日在上海市浦东新区建陆路 378 号以现场会议的方式召开。本次 会议的通知和会议资料已于 2023 年 8 月 18 日以电子邮件方式发出。本次会议应 出席监事 3 名，实际出席监事 2 名，监事邢永刚先生因工作原因未能出席本次会 议，委托监事左永华先生代为行使表决权。会议由监事左永华先生主持，公司董 事会秘书列席了会议。会议的召集、召开符合《公司法》和《公司章程》的有关 规定，会议合法有效。 二、监事会会议审议情况 监事会就公司 2023 年半年度报告确认如下：公司 2023 年半年度报告的编制 和审议程序符合法律、法规及公司内部相关管理制度的规定，真实、准确、完整 地反映了公司 2023 年半年度的财务状况和经营成果，其中不存在虚 ...

上海现代制药股份有限公司 关于国药集团财务有限公司的 2023 年半年度风险评估报告 根据《上海证券交易所上市公司自律监管指引第 5 号—交易与关联交易》的 要求，上海现代制药股份有限公司（以下简称国药现代）通过查验国药集团财务 有限公司（以下简称国药财务或公司）的《企业法人营业执照》《金融许可证》 等证件资料，并审阅了国药财务截至 2023 年 6 月 30 日的财务报告以及风险指标 等必要信息，对国药财务的经营资质、业务和风险状况进行了评估，具体情况报 告如下： 一、国药财务基本情况 国药财务成立于2012年2月23日，是经中国银行业监督管理委员会（以下简 称银监会）批准成立的非银行金融机构。 注册地址：北京市海淀区知春路20号 法定代表人：杨珊华 金融许可证机构编码：L0145H211000001 统一社会信用代码：9111000071783212X7 经营范围：1、对成员单位办理财务和融资顾问、信用鉴证及相关的咨询、 代理业务；2、协助成员单位实现交易款项的收付；3、对成员单位提供担保；4、 办理成员单位之间的委托贷款及委托投资（仅限固定收益类有价证券投资）；5、 对成员单位办理票据承兑与贴现；6、办 ...

证券代码：600420 证券简称：国药现代 公告编号：2023-087 上海现代制药股份有限公司 本次章程修订尚需提交公司 2023 年第二次临时股东大会审议，经特别决议 通过后生效。 特此公告。 上海现代制药股份有限公司董事会 2023 年 8 月 29 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海现代制药股份有限公司（以下简称公司）于 2023 年 8 月 28 日召开第八 届董事会第九次会议，审议通过了《关于变更注册资本暨修订<公司章程>的议案》。 公司 2019 年度公开发行上市的可转换公司债券已于 2023 年 6 月 16 日完成 转股暨赎回，2023 年 2 月 1 日至 2023 年 6 月 15 日期间，因可转换公司债券转 股，公司股本数量增加 169,086,659 股，公司的注册资本也将由 1,172,086,033 元 相应变更为 1,341,172,692 元，并对《公司章程》相关内容作出如下相应修订： | 原条款 | | | | 拟修订 | | --- | --- | --- | --- ...

证券代码：600420 证券简称：国药现代 公告编号：2023-088 股东大会召开日期：2023年9月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年第二次临时股东大会 (二) 股东大会召集人：董事会 上海现代制药股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票 相结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2023 年 9 月 13 日 14 点 00 分 召开地点：上海市浦东新区建陆路 378 号五楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2023 年 9 月 13 日 至 2023 年 9 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大 ...

中信证券股份有限公司 关于上海现代制药股份有限公司与国药集团药业股份有限公司 签署委托管理协议暨关联交易的核查意见 中信证券股份有限公司（以下简称 "保荐人"）作为上海现代制药股份有限公司 （以下简称"国药现代"或"公司"）2019年公开发行可转换公司债券、2022年非公开发 行A股股票的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市 规则》《上海证券交易所上市公司自律监管指引第1号——规范运作》《上海证券交易所上市公 司自律监管指引第5号——交易与关联交易》等有关法律法规规定，就公司与国药集团药业 股份有限公司（以下简称"国药股份"）签署委托管理协议暨关联交易所涉及事项进行了 核查，核查情况如下： 一、关联交易概述 （一）本次交易基本情况及交易目的 鉴于国药股份控股子公司国瑞药业与国药现代存在同业竞争，中国医药集团有限公司 （以下简称"国药集团"）于2018年8月出具承诺："自承诺出具之日起五年内，将推动 国药控股、国药股份通过包括但不限于择机将国瑞药业注入国药现代、将国瑞药业出售给 无关联关系的独立第三方、调整国瑞药业产品结构等方式予以处置。" 为履行上述承诺，避免上市公司之间的同业 ...

证券代码：600420 证券简称：国药现代 公告编号：2023-083 上海现代制药股份有限公司 第八届董事会第九次会议决议公告 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过了《2023 年半年度募集资金存放与实际使用情况的专项报告》。 独立董事就该报告发表独立意见表示认可。 上海现代制药股份有限公司（以下简称公司）第八届董事会第九次会议，于 2023 年 8 月 28 日在上海市浦东新区建陆路 378 号以现场会议的方式召开。本次 会议的通知和会议资料已于 2023 年 8 月 18 日以电子邮件方式发出。本次会议应 参会董事 9 名，实际参会董事 9 名。会议由董事长董增贺先生主持，公司部分监 事和高级管理人员列席了会议。本次会议的召集和召开程序符合《公司法》和《公 司章程》的有关规定，会议合法有效。 二、董事会会议审议情况 本次会议审议并通过了如下事项： 1、审议通过了《2023 年半年度报告及摘要》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 公司 2023 年半年度报告全文及摘要详见 www.sse.com.cn。 本公司董事会及全体董事保证本公告内容不存在任何虚假 ...

证券代码：600420 证券简称：国药现代 公告编号：2023-034 债券代码：110057 债券简称：现代转债 重要内容提示： 会议召开时间：2023 年 05 月 12 日（星期五）下午 13:00-14:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 投资者可于 2023 年 05 月 06 日（星期六）至 05 月 11 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 xd_zhengquanban@sinopharm.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 上海现代制药股份有限公司（以下简称公司）已于 2023 年 03 月 30 日发布 了 2022 年度报告，并于 2023 年 04 月 26 日发布了 2023 年第一季度报告。为便 于广大投资者更加全面深入地了解公司 2022 年度及 2023 年第一季度经营成果、 财务状况，公司计划于 2023 年 05 月 12 日下午 13:00-14:30 参加沪市主 ...

Financial Performance - The net profit attributable to shareholders increased by 130.87% compared to the same period last year, driven by a stabilization in the pharmaceutical terminal market[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 157.99%, with a decrease in expense ratios by 5.45 percentage points year-on-year[7]. - The net profit attributable to shareholders for Q1 2023 was ¥179,223,645.37, representing a significant increase of 130.87% from the previous year[37]. - The net profit for the first quarter of 2023 was RMB 274,261,401.19, compared to RMB 136,080,784.29 in the same period of 2022, showing an increase of about 101.9%[48]. - The company's net profit for Q1 2023 was $18.71 million, a decrease from $157.78 million in Q1 2022, reflecting a decline of 88.2%[63]. - The company reported a comprehensive income of $18.68 million for Q1 2023, down from $158.18 million in Q1 2022, a decline of 88.2%[63]. Revenue and Sales - Operating revenue for Q1 2023 reached ¥3,417,169,160.61, up from ¥3,244,221,809.47 in Q1 2022, reflecting a growth in sales[21]. - The company's operating revenue for Q1 2023 was ¥254,001,223.34, a decrease of 43.2% compared to ¥446,817,438.79 in Q1 2022[31]. - Cash received from sales of goods and services in Q1 2023 totaled ¥2,458,359,184.90, a decrease of 10.4% compared to ¥2,744,038,557.81 in Q1 2022[50]. Cash Flow and Liquidity - Cash flow from operating activities decreased by 35.33% year-on-year, primarily due to a reduction in cash inflow from sales orders settled with advance payments in Q4 2022[7]. - The net cash flow from operating activities for Q1 2023 was ¥269,560,307.91, a decrease of 35.33% compared to the same period last year[37]. - The company experienced a net cash outflow from financing activities of ¥797,465,602.21 in Q1 2023, compared to a smaller outflow of ¥217,174,350.82 in Q1 2022[28]. - Cash inflow from operating activities for Q1 2023 was $397.19 million, up from $328.82 million in Q1 2022, representing a 20.8% increase[57]. - Net cash flow from operating activities for Q1 2023 was -$8.57 million, a significant decline from $165.22 million in Q1 2022[57]. - Cash and cash equivalents at the end of Q1 2023 were $2.38 billion, up from $1.10 billion at the end of Q1 2022, an increase of 116.7%[65]. Assets and Liabilities - The company reported a total asset value of ¥18,957,972,176.28 as of March 31, 2023, down from ¥19,630,346,096.40 at the end of 2022[18]. - The total assets at the end of Q1 2023 were ¥18,957,972,176.28, a decrease of 3.43% from the end of the previous year[37]. - The total liabilities decreased, with short-term borrowings dropping significantly from ¥321,138,719.45 to ¥25,026,736.06[18]. - The total liabilities decreased to RMB 6,531,019,691.95 from RMB 7,477,624,438.48, indicating a reduction of approximately 12.7%[46]. - Total liabilities decreased to $3.93 billion as of March 31, 2023, from $5.22 billion at the end of 2022, a reduction of 24.7%[61]. Equity and Retained Earnings - The company's total equity increased to RMB 12,426,952,484.33 as of March 31, 2023, up from RMB 12,152,721,657.92 at the end of 2022, representing a growth of approximately 2.3%[46]. - The company's retained earnings rose to RMB 5,065,125,677.15 as of March 31, 2023, compared to RMB 4,885,902,031.78 at the end of 2022, marking an increase of approximately 3.7%[46]. Research and Development - Research and development expenses for Q1 2023 were ¥110,631,302.54, compared to ¥116,995,102.84 in Q1 2022, indicating a focus on cost control[21]. - Research and development expenses for Q1 2023 were ¥17,406,876.57, slightly down from ¥18,962,920.22 in Q1 2022[31]. Dividends and Shareholder Returns - The company paid dividends to minority shareholders amounting to ¥5,107,617.57 in Q1 2023, up from ¥2,828,123.93 in Q1 2022[28]. - The basic earnings per share for Q1 2023 was ¥0.1529, an increase of 102.25% year-over-year[37]. - Basic earnings per share (EPS) for Q1 2023 was ¥0.1529, up from ¥0.0756 in Q1 2022, indicating an increase of 102.4%[49].

Internal Control and Compliance - The company engaged Tianjian Accounting Firm to audit the effectiveness of its internal control, resulting in a standard unqualified opinion in the 2022 internal control audit report disclosed on March 30, 2023[3]. - The company has committed to ensuring that its actions do not harm the interests of shareholders and to comply with regulatory requirements[20]. - The company will strictly comply with the regulations of the China Securities Regulatory Commission and the Shanghai Stock Exchange after the completion of the transaction, ensuring the independence of the listed company in personnel, assets, finance, and business[18]. - The company guarantees not to occupy the funds and assets of the listed company and its subsidiaries in any way after the transaction is completed[18]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[22]. - The company is committed to ensuring the accuracy and completeness of its financial reporting, as confirmed by a standard unqualified audit report[83]. Environmental Protection and Sustainability - The company’s environmental protection facilities, including wastewater treatment and air emission control systems, are operating normally, with ongoing enhancements to ensure compliance with environmental standards[6]. - The company has implemented annual emergency drill plans for environmental incidents, improving coordination and response capabilities to unexpected environmental events[7]. - The company has committed to reducing carbon emissions and has taken measures to achieve this goal, although specific results were not detailed in the report[10]. - The company has established a monitoring system for environmental facilities, including daily operation protocols and maintenance schedules, to ensure compliance and operational efficiency[6]. - The company has a dedicated team responsible for the operation and monitoring of environmental facilities, with some units outsourcing management to third-party professionals[6]. - The company has developed a comprehensive environmental emergency response plan, which has been filed for regulatory review[7]. Financial Performance - The company's operating revenue for the reporting period was ¥12,959,320,533.56, a decrease of 7.07% compared to ¥13,944,948,270.25 in the previous year[52]. - Operating costs increased to ¥8,024,562,526.12, reflecting a rise of 2.25% from ¥7,848,140,984.30 in the prior year[52]. - The net profit attributable to shareholders of the listed company for 2022 was ¥627,794,828.71, representing a year-on-year increase of 10.47% compared to ¥568,280,771.91 in 2021[96]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥552,660,279.79, an increase of 11.17% from ¥497,119,038.98 in the previous year[96]. - The net cash flow from operating activities surged by 70.01% to ¥2,855,633,105.16, compared to ¥1,679,662,393.87 in the previous year[52]. - The company reported a balance of distributable profits for shareholders of ¥2,601,334,684.75 at the end of the reporting period[102]. Research and Development - The company’s R&D expenses were ¥520,922,635.17, down 11.59% from ¥589,184,570.70 in the previous year[52]. - The company launched 51 new patents during the reporting period, including 17 invention patents, enhancing its innovation capabilities[135]. - The company is focusing on the development of controlled-release, membrane, and transdermal patch technologies as part of its innovation strategy[135]. - The company has established a multi-level R&D system focusing on five key therapeutic areas, enhancing innovation capabilities[62]. - The company is actively promoting centralized procurement management to reduce costs and improve efficiency[62]. Market and Sales Strategy - The company achieved operating revenue of 12.959 billion yuan, a year-on-year decrease of 7.07%, with over 1 billion yuan products increasing to 31, accounting for 72% of sales[122]. - The company is focusing on market expansion through the development of new chemical drugs and active pharmaceutical ingredients[74]. - The company has established a nationwide sales network through a combination of distribution, agency, and academic promotion strategies[130]. - The company plans to continue expanding its market presence and enhancing its product offerings in the health and wellness sector[130]. - The company is exploring CMO and CDMO business opportunities to enhance manufacturing efficiency through external resource extension and internal collaboration[62]. Corporate Governance and Shareholder Relations - The company has made commitments to minimize related party transactions and ensure fair pricing in any necessary transactions, with a focus on protecting the rights of all shareholders[17]. - The company commits to not using related party transactions to illegally transfer funds or profits from China National Pharmaceutical Modern[19]. - The company will bear all losses caused to China National Pharmaceutical Modern and other shareholders if it violates the commitments made[19]. - The company will not intervene in the management activities of the company or infringe on its interests regarding the issuance of convertible bonds[19]. - The company has committed to ensuring that its future equity incentive plans are linked to the execution of return compensation measures[20]. Asset Management and Financial Health - Cash and cash equivalents at the end of the period amounted to ¥6,148,196,232.13, representing 31.32% of total assets, an increase of 43.51% compared to the previous period[198]. - The company reported a significant increase in prepayments, which rose to ¥275,949,663.45, representing 1.41% of total assets, a 76.74% increase compared to the last period[198]. - The total amount of short-term borrowings decreased to ¥321,138,719.45, which is 1.64% of total assets, reflecting a substantial decline of 77.17% from the previous period[198]. - The company holds overseas assets valued at ¥1,173,602.39, which constitutes 0.01% of total assets[199]. - The company has restricted cash of ¥249,000,000.00 due to time deposits, and additional restricted amounts for guarantee deposits and frozen funds[200].

Financial Performance - The company's operating revenue for Q3 2022 was ¥3,332,135,975.28, representing an increase of 8.26% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥201,521,805.81, a decrease of 1.85% year-on-year, while the year-to-date net profit decreased by 32.48% to ¥426,372,120.55[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥161,261,302.61, down 3.41% year-on-year, with a year-to-date decrease of 38.39% to ¥356,018,230.66[5]. - The basic earnings per share for Q3 2022 was ¥0.1963, reflecting a decrease of 32.48% compared to the same period last year[5]. - The diluted earnings per share for Q3 2022 was ¥0.1732, down 30.90% year-on-year[7]. - The weighted average return on equity for Q3 2022 was 2.26%, a decrease of 0.14 percentage points compared to the previous year[7]. - Total operating revenue for the first three quarters of 2022 was CNY 9,719,160,020.44, a decrease of 9.3% compared to CNY 10,710,170,799.63 in the same period of 2021[26]. - Net profit for the first three quarters of 2022 was CNY 604,173,833.75, a decline of 24.4% from CNY 799,702,644.46 in the same period of 2021[29]. - Basic earnings per share for the first three quarters of 2022 were CNY 0.4152, down from CNY 0.6149 in the same period of 2021[31]. Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥18,500,232,428.08, a decrease of 2.99% compared to the end of the previous year[7]. - As of September 30, 2022, total assets amounted to ¥18,500,232,428.08, a decrease from ¥19,069,961,392.45 as of December 31, 2021, reflecting a decline of approximately 2.99%[24]. - Total current assets were reported at ¥10,590,812,386.23, down from ¥10,886,446,261.52, indicating a decrease of about 2.71%[18]. - Total liabilities decreased to ¥7,792,999,911.35 from ¥8,700,102,902.92, reflecting a reduction of about 10.43%[22]. - The total liabilities decreased to ¥4,457,324,838.87 as of September 30, 2022, from ¥4,685,533,578.22 at the end of 2021, representing a reduction of 4.9%[44]. - The total equity increased to ¥7,898,062,555.98 as of September 30, 2022, compared to ¥7,383,207,177.95 at the end of 2021, reflecting a growth of 7%[44]. Cash Flow - The net cash flow from operating activities for the year-to-date period increased by 43.19% to ¥1,965,774,395.17[11]. - Cash flow from operating activities was CNY 8,912,017,188.80 for the first three quarters of 2022, a decrease from CNY 9,885,981,372.64 in the same period of 2021[33]. - Net cash flow from operating activities for the first three quarters of 2022 was CNY 1,965,774,395.17, an increase of 43.3% compared to CNY 1,372,864,799.01 in the same period of 2021[35]. - The cash flow from operating activities for the first three quarters of 2022 was ¥846,998,456.75, a substantial increase from ¥157,063,234.34 in the same period of 2021[54]. Expenses - Total operating costs for the first three quarters of 2022 were CNY 9,013,362,094.64, down 8.3% from CNY 9,829,243,735.14 in the previous year[26]. - Research and development expenses for the first three quarters of 2022 amounted to CNY 360,086,744.11, a slight decrease of 6.8% compared to CNY 386,254,592.42 in 2021[26]. - Sales expenses decreased to CNY 2,189,914,277.14 in the first three quarters of 2022, down 20.6% from CNY 2,759,870,569.86 in the same period of 2021[26]. - The company reported a significant improvement in credit impairment losses, with a loss of CNY 4,784,358.27 in 2022 compared to a loss of CNY 29,837,513.78 in 2021[29]. - The company's sales expenses surged to ¥496,227,887.10 in the first three quarters of 2022, compared to ¥113,917,294.89 in the same period of 2021, reflecting a significant increase of 336.5%[46]. Cash Management - The company's cash and cash equivalents increased to ¥4,382,038,580.45 from ¥4,284,240,287.88, showing a growth of approximately 2.29%[17]. - Cash and cash equivalents at the end of the reporting period were CNY 4,144,908,326.08, up from CNY 3,778,658,665.42 at the end of 2021, marking an increase of 9.7%[36]. - The company reported a cash decrease of approximately -$2.22 million in 2022, compared to a larger decrease of -$114.47 million in 2021, indicating an improvement in cash management[55]. - The company’s cash flow from investment activities showed a positive turnaround, moving from a negative cash flow in 2021 to a positive cash flow in 2022[55]. Market Conditions - The company attributed the decline in net profit to factors such as the resurgence of COVID-19, market competition, and rising prices of raw materials and fuels[9].